Can insulin resistance increase hepatic VLDL production and raise triglycerides and apoB particle numbers?

Insulin resistance serves as a key driver of atherogenic dyslipidemia, directly altering hepatic lipid metabolism and particle secretion.

Mechanistic pathways of hepatic overproduction

• Impaired apoB-100 degradation: In healthy states, insulin acts as an acute brake on VLDL production by promoting the degradation of apolipoprotein B-100 (apoB-100). Under insulin-resistant conditions, this regulatory suppression is lost, allowing nascent apoB-100 to escape degradation.
• Upregulated de novo lipogenesis (DNL): Through pathway-selective signaling, insulin's stimulatory effect on lipogenesis is preserved. Chronic hyperinsulinemia upregulates SREBP-1c and ChREBP, driving hepatic DNL. Stable-isotope tracer studies show that DNL-derived fatty acids rise from less than 10% of total VLDL-triglycerides in healthy states to 15–25% in insulin-resistant non-alcoholic fatty liver disease (NAFLD).
• VLDL1 hypersecretion: Elevated microsomal triglyceride transfer protein (MTP) activity, combined with a larger hepatic triglyceride pool, facilitates the assembly and hypersecretion of large, triglyceride-rich VLDL1 particles.

Impact on circulating triglycerides and apoB

• Systemic hypertriglyceridemia: Because VLDL is the primary vehicle for exporting endogenous lipids from the liver, an increased VLDL-triglyceride secretion rate directly outpaces peripheral clearance, driving up plasma triglyceride levels.
• Increased apoB particle count: Each VLDL particle is assembled with exactly one molecule of apoB-100. Due to this strict 1:1 stoichiometry, the overproduction and secretion of VLDL particles directly elevate the total concentration of circulating, atherogenic apoB-containing particles.

Bottom line

• Bottom line: Insulin resistance directly increases hepatic VLDL secretion. This occurs through a dual mechanism where failed insulin-mediated apoB-100 degradation combines with hyperactivated de novo lipogenesis and elevated MTP activity, ultimately raising both circulating triglycerides and the total number of atherogenic apoB-containing particles.